Exasperated at Teva Pharmaceutical Industries Ltd.’s latest attempt to block approval of ANDAs for generic Copaxone (glatiramer), FDA told a district court that it should decline Teva’s “remarkable invitation” to determine whether an application should be approved before the agency decides to do so.
In a May 12 filing, FDA asked the court to toss Teva’s suit against the agency, which seeks...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?